CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is currently classified as Healthcare Diagnostics within Biotechnology & Medical Research (Healthcare). Classification confidence: 0.92 (verified market data). Capital structure on the latest snapshot: total assets 7,135,422,000 USD, total equity 3,164,630,000, short-term debt 166,000, long-term debt 2,136,360,000. Net cash position is approximately -1,922,756,000 USD. Profitability profile: revenue 4,015,382,000, gross profit 0, operating income 25,162,000, net income -144,338,000. Return on equity ~-4.6%. Return on assets ~-2.0%. Operating-cash-flow to net-income ratio is -5.11. Risk profile from automated assessment: liquidity risk medium, dilution risk medium. Flags: Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk.. Management commentary signal: ther consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement..
Business. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. is classified under Healthcare / Biotechnology & Medical Research and appears not currently profitable on the latest normalized snapshot.
Classification. Classification confidence is 0.92 based on verified market data; matched terms: Biotechnology & Medical Research, Pharmaceuticals & Medical Research, Healthcare.
- Return on equity is about -4.6%.
- Debt to equity is about 0.68x.
- Management signal detected: ther consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.
- Net cash is negative after subtracting total debt.
- Source documents mention dilution or offering risk.